Optimizing the clinical effectiveness of Theta Burst Stimulation (TBS) treatment for individuals with depression (Study 1)
- Conditions
- Treatment resistant depressionMental Health - Depression
- Registration Number
- ACTRN12622001250729
- Lead Sponsor
- Australian National University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 240
Diagnosis of major depressive episode (MDE), in accordance with the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5), in the context of unipolar major depressive disorder or bipolar affective disorder.
18-85 years of age.
Treatment resistant depression at Stage I of the Thase and Rush classification.
Hamilton Depression Rating Scale (HAMD) score of >17 (moderate – severe depression).
No increase or initiation of new antidepressant therapy in the four weeks prior to screening.
Demonstrated capacity to give informed consent.
Inability to provide informed consent
Medically unstable patients
Concomitant neurological disorder or a history of a seizure disorder.
Patients who are pregnant or breastfeeding.
Active suicidal intent
Any psychotic disorder or current active psychotic symptoms
Patients who have intracranial implants deemed unsafe for TMS.
Significant difficulties with English communication and comprehension.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Total score on the 17 item Hamilton Depression Rating Scale (HAMD).[ The primary analysis will be on mean HAMD scores from baseline to treatment end (completion of 35 treatment sessions) for each primary comparison.]
- Secondary Outcome Measures
Name Time Method